Navigation Links
Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers' Diarrhea Patch Vaccine
Date:8/19/2007

lly, causing 380,000 deaths each year.

ABOUT IOMAI CORPORATION

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.

Some matters discussed in this press release constitute "forward-looking statements" that involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Such forward-looking statements include statements about the predictability of the data from this trial in preventing travelers' diarrhea in the elderly, timing and expectation for Iomai commencing Phase 3 studies for this product candidate, and bringing the product candidate to market; the potential size of the market for an ETEC vaccine; the applicability of TCI technology to other pathogens; and that, if approved, Iomai's vaccine would be the first available in the U.S. Applicable risks and uncertainties include, among others, that Iomai may not be able to enroll sufficient numbers of patients in future clinical trials; that future clinical trials may not replicate results seen in the trial described in this press release; that Iomai may be unable to obtain the regulatory approval
'/>"/>

SOURCE Iomai Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Iomai to Announce Results From Phase 1 Influenza Trial and Host Webcast Tomorrow
2. Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers Diarrhea Stimulates Immune Response Even at Low Doses
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
8. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
9. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (NYSE: RMD ), a pioneer and innovator in ... sleep apnea solutions specifically for women, is launching a new ... night,s sleep. The Better Sleep For Women ... just part of living a busy life. It will encourage ... health, essential to not only living an active lifestyle but ...
(Date:10/1/2014)... , Oct. 1, 2014  Varian Medical Systems ... will report results for the fourth quarter of fiscal ... Wednesday, October 22, 2014.  The news release will be ... at 2:00 p.m. PT.  The news release and a ... on the company website at: www.varian.com/investor .  To ...
(Date:10/1/2014)... , Oct. 1, 2014   Royal ... PHIA) today announced its eCareCoordinator and eCareCompanion telehealth ... Food and Drug Administration (FDA). A part of ... programs , eCareCoordinator and eCareCompanion are focused on ... first clinical applications to be available through the ...
Breaking Medicine Technology:ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4
... Jan. 11, 2011 Reportlinker.com announces that a ... catalogue: Novo Nordisk A/S: PharmaVitae ... Introduction This ... Novo Nordisk in the prescription pharmaceutical sector. The ...
... 11, 2011 Reportlinker.com announces that ... available in its catalogue: ... New pricing rules set to negatively ... internationally http://www.reportlinker.com/p0360217/Germany-Pharmaceutical-Market-Overview-–-New-pricing-rules-set-to-negatively-impact-drug-sales-both-domestically-and-internationally.html ...
Cached Medicine Technology:Reportlinker Adds Novo Nordisk A/S: PharmaVitae Profile 2Reportlinker Adds Germany Pharmaceutical Market Overview - New pricing rules set to negatively impact drug sales both domestically and internationally 2
(Date:10/1/2014)... beta-amyloid is strongly associated with Alzheimer,s disease; however, researchers ... is the causal agent of the onset and development ... is that beta-amyloid is not harmful when found in ... it self-assembles to form the so-called amyloid fibrils , ... alone, but with multiple ones because each aggregate of ...
(Date:10/1/2014)... by the Engineering and Physical Sciences Research Council ... UK,s vital industrial control systems which run, for ... and the rail network. , The research ... or malware infiltrating the systems behind our critical ... Trustworthy Industrial Control Systems (RITICS), based at Imperial ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog post ... , Senior citizens can qualify for affordable term ... seniors who are over 50 years old. Some term ... medical examination. , Term life insurance with a simplified ... qualify. Having life insurance during retirement is important for ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining ... smokers. , Smoking will always have a negative impact ... best method to find affordable coverage. Insurance brokerage websites ... , Whole life insurance premiums will be fixed ... coverage is permanent, the initial rates are very ...
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2
... new study shows men with prostate cancer who receive a ... reduce // the risk of recurrence after surgery may be ... showed men treated with androgen deprivation therapy (ADT) after prostate ... most common among women. Men who are older, smoke, or ...
... with the oral drug bosentan (Tracleer) has led to ... hypertension ( PAH) // . ,PAH is usually ... believed to cause the overproduction of endothelin, which increases ... This chronic obstruction leads to PAH, a condition that ...
... intense course of radiation after a lumpectomy may be ... on findings of a recent study. Standard treatment for ... weeks of radiation daily after undergoing surgery , however ... treatment is a major inconvenience leading them to choose ...
... a urinary tract infection can increase your chances of having ... few days, say researchers based on findings of a recent ... anytime we have an infection, to atherosclerosis, or clogging of ... of infections, some have speculated they, too, could aggravate the ...
... the existing drugs on the market are losing their ... bacteria hence researchers feel that the ocean is a ... ,More than 1 million microorganisms fill every milliliter of ... for some of our deadliest diseases. Many marine organisms ...
... J. Rutter, a well known scientist and accomplished businessman ... patent applications,has announced intention to set up a high ... of "Hemogenomics", which will be a marketing, selling and ... the sidelines of the BioAsia 2004 conference Bangalore on ...
Cached Medicine News:
Based on the clinically proven ACS MULTI-LINK Stent, ULTRA is a coronary stent system specifically designed for use in larger vessels. This innovative system utilizes a unique stent pattern to give y...
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Now available in 2.75-mm diameters, the S660 small vessel coronary stent expands your treatment options for accurate sizing and precision stenting....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
Medicine Products: